SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi
Idag, 16:31
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi
PR Newswire
NEW YORK, Nov. 14, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tvardi To Contact Him Directly To Discuss Their Options
If you suffered losses in Tvardi and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) .
[You may also click here for additional information]
NEW YORK , Nov. 14, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc.. ("Tvardi" or the "Company") (NASDAQ: TVRD).
Faruqi & Faruqi is a leading national securities law firm with offices in New York , Pennsylvania , California and Georgia . The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com .
On Monday, October 13, 2025 , Tvardi Therapeutics, Inc. saw its shares plummet over 80% after disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in Forced Vital Capacity (FVC), the Company concluded that the study did not meet its goals. Preliminary data demonstrated patients' baseline characteristics were similar across treatment arms, with the exception of percent predicted FVC, which was lower in the placebo-treated patients compared to the TTI-101-treated arms.
To learn more about the Tvardi Therapeutics, Inc. investigation, go to www.faruqilaw.com/TVRD or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) .
Follow us for updates on LinkedIn , on X , or on Facebook .
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
SOURCE Faruqi & Faruqi, LLP
Ämnen i artikeln
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi
Idag, 16:31
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi
PR Newswire
NEW YORK, Nov. 14, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tvardi To Contact Him Directly To Discuss Their Options
If you suffered losses in Tvardi and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) .
[You may also click here for additional information]
NEW YORK , Nov. 14, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc.. ("Tvardi" or the "Company") (NASDAQ: TVRD).
Faruqi & Faruqi is a leading national securities law firm with offices in New York , Pennsylvania , California and Georgia . The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com .
On Monday, October 13, 2025 , Tvardi Therapeutics, Inc. saw its shares plummet over 80% after disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in Forced Vital Capacity (FVC), the Company concluded that the study did not meet its goals. Preliminary data demonstrated patients' baseline characteristics were similar across treatment arms, with the exception of percent predicted FVC, which was lower in the placebo-treated patients compared to the TTI-101-treated arms.
To learn more about the Tvardi Therapeutics, Inc. investigation, go to www.faruqilaw.com/TVRD or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) .
Follow us for updates on LinkedIn , on X , or on Facebook .
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
SOURCE Faruqi & Faruqi, LLP
Ämnen i artikeln
Nibes rapport
Aktieråd
Börsprognos
Aktieanalyser
Förvaltarnas investeringar
Placerapodden
Nibes rapport
Aktieråd
Börsprognos
Aktieanalyser
Förvaltarnas investeringar
Placerapodden
Marknadsöversikt
1 DAG %
Senast
1 mån
